Search results
Results from the WOW.Com Content Network
It is one of the largest recoveries against a pharmaceutical company in U.S. history. The total settlement remained the largest against a pharmaceutical company in a non-intervened False Claims Act case until a July 2017 settlement against Celgene Corporation exceeded it, as the civil settlement in that case was $280 million while the civil ...
By 2008 Glenmark was the fifth-biggest pharmaceutical company in India. [5] By 2011 the founder of the company was one of the richest men in India, [6] and Glenmark had worldwide sales of $778 million, a 37% increase over the last year's sales; the growth was driven by Glenmark's entry into the US and European generics markets. [7]
The settlement amount includes both the civil (False Claims Act) settlement and criminal fine. Glaxo's $3 billion settlement included the largest civil False Claims Act settlement on record, [1] and Pfizer’s $2.3 billion ($3.5 billion in 2022) settlement including a record-breaking $1.3 billion criminal fine. [2]
The site enables you to find more than just reverse lookup names; you can search for addresses, phone numbers and email addresses. BestPeopleFinder gets all its data from official public, state ...
• Communication surcharges - We answer to a higher calling - the phone company. If you connect to AOL using a long-distance number or AOLnet 800 number, you’ll see these surcharges in addition to your monthly subscription fee. We don’t refund these charges, so check with your phone company to make sure your selected access numbers are local.
German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements, the U ...
Reverse payment patent settlements, also known as "pay-for-delay" agreements, [1] are a type of agreement that has been used to settle pharmaceutical patent infringement litigation (or threatened litigation), in which the company that has brought the suit agrees to pay the company it sued. That is, the patent holder pays the alleged infringer ...
(Reuters) -Britain's AstraZeneca said it will pay $425 million to settle lawsuits in the United States that claimed its heartburn drugs Nexium and Prilosec caused chronic kidney disease.